[Double-blind clinical study with placebo versus bumadizone-Ca in 113 patients with rheumatism].
D000328:Adult; D000368:Aged; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001799:Blood Sedimentation; D001831:Body Temperature / Q000187:drug effects; D004285:Dogs; D004487:Edema / Q000188:drug therapy; D005260:Female; D006073:Gout / Q000188:drug therapy; D006801:Humans; D008297:Male; D008314:Malonates / Q000627:therapeutic use*; D051379:Mice; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy; D010113:Oxyphenbutazone / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D010659:Phenylhydrazines / Q000627:therapeutic use*; D010919:Placebos; D011817:Rabbits; D051381:Rats; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D008314:Malonates; D010659:Phenylhydrazines; D010919:Placebos; D010113:Oxyphenbutazone
Klinische Prüfung im Doppelblindversuch Plazebo gegen Bumadizon-Ca bei 113 Rheumafällen.